Exploring a new treatment approach for rheumatoid arthritis through protein signaling.
Modulation of Protein S-nitrosylation Signaling as a Potential Therapeutic Breakthrough in Rheumatoid Arthritis
This study is exploring a new way to help people with rheumatoid arthritis by using a treatment that targets a specific enzyme to reduce inflammation and protect your joints, and we’ll be looking to see if it helps improve your symptoms and joint health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gsno Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Shelton, United States) |
| Project ID | NIH-10817318 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic strategy for rheumatoid arthritis (RA) by targeting protein S-nitrosylation signaling. The approach involves inhibiting an enzyme called GSNOR, which is linked to oxidative stress and inflammation in RA. By increasing levels of a protective molecule, GSNO, the research aims to restore healthy signaling pathways that can reduce inflammation and protect joint tissues. Patients may be monitored for improvements in symptoms and joint health as part of this innovative treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who are experiencing significant inflammation and joint damage.
Not a fit: Patients with rheumatoid arthritis who are not responsive to new therapeutic approaches or those with contraindications to the study drug may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly alleviates symptoms and slows the progression of rheumatoid arthritis.
How similar studies have performed: While the specific approach of targeting GSNOR for RA is novel, similar strategies targeting oxidative stress and inflammation have shown promise in other autoimmune conditions.
Where this research is happening
Shelton, United States
- Gsno Therapeutics, INC. — Shelton, United States (Active)
Researchers
- Principal investigator: Bradley, Matthews Ogden — Gsno Therapeutics, INC.
- Study coordinator: Bradley, Matthews Ogden
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.